Title:

Oligodendrocytes use postsynaptic proteins to coordinate myelin formation on axons of distinct neurotransmitter

classes

Authors:

Natalie J. Carey, Caleb A. Doll, and Bruce Appel

Section of Developmental Biology, Department of Pediatrics, University of Colorado, Anschutz Medical Campus,

Aurora, Colorado, USA, 80445

Correspondence:

Bruce Appel

bruce.appel@cuanschutz.edu

University of Colorado Anschutz Medical Campus, MS8108, Aurora, CO, 80045, USA

ABSTRACT

Axon myelination can tune neuronal circuits through placement and modulation of different patterns of myelin

sheaths on distinct types of axons. How myelin formation is coordinated on distinct axon classes remains largely

unknown. Recent work indicates neuronal activity and vesicle release promote myelin formation, and myelin-

producing oligodendrocytes express canonical postsynaptic factors that potentially facilitate oligodendrocyte-

axon interaction for myelin ensheathment. Here, we examined whether the inhibitory postsynaptic scaffold

protein Gephyrin (Gphn) mediates selective myelination of specific axon classes in the larval zebrafish.

Consistent with this possibility, Gphn was enriched in myelin on GABAergic and glycinergic axons. Strikingly, in

gphnb deficient larvae, myelin sheaths were longer specifically on GABAergic axons, and the frequency of myelin

placement shifted toward glutamatergic axons at the expense of GABAergic axons. Collectively, our results

indicate that oligodendrocytes use postsynaptic machinery to coordinate myelin formation in an axon identity-

dependent manner.

INTRODUCTION

Oligodendrocytes (OLs) are glial cells in the central nervous system (CNS) that produce myelin, a lipid-

rich membrane that wraps around axons to provide metabolic and trophic support and increase action potential

velocity. A single OL can myelinate dozens of axons simultaneously[1], including different classes of axons defined

by distinct neurotransmission profiles. Because different neuron types have different axon lengths, firing rates,

and energetic demands, the amount and composition of myelin on axons can play a crucial role in signal timing

within a neural circuit.

Neural circuits require a balance of excitatory and inhibitory influence to achieve regulated output, such

as the coordinated locomotion generated by the spinal cord. Canonically, glutamatergic neurons provide

excitatory input and γ-amino butyric (GABAergic)/glycinergic neurons provide inhibitory influence on circuit

output[2-4]. Critically, glutamatergic, GABAergic, and glycinergic neurons signal through unique molecular

machinery where their axon terminals create synapses with the appropriate postsynaptic terminal. Postsynaptic

scaffold proteins provide specificity for synapse formation by anchoring receptors and cell adhesion molecules

that are enriched at unique synapses. Postsynaptic Density 95 protein (PSD95) is the primary scaffold protein

at excitatory glutamatergic synapses, whereas Gephyrin (Gphn) is the postsynaptic scaffold at inhibitory

GABAergic and glycinergic synapses[3-9]. This specificity of synaptic communication is necessary in complex

circuits to coordinate neuronal firing and generate functional behaviors such as locomotion.

Remarkably, OLs produce myelin sheaths with variable lengths and thicknesses on individual axons[10-11],

and myelin patterns on distinct classes of axons vary across neuron type and brain region[12-16]. What mechanisms

might convey specificity in myelin formation on distinct axon classes? One possibility is that OLs engage with

axons using mechanisms similar to synapse formation where a myelin sheath contacts an axon at an axo-sheath

interface. Several findings support this possibility. First, neuronal activity promotes myelin formation through

vesicle release along the axon[15,17-19]. This vesicular release is accompanied by axonal Ca^{2+} events at sites where

myelin growth will subsequently occur[15]. Second, gene expression profiling studies show that OL lineage cells

(OLCs) express many genes that encode postsynaptic proteins such as PSD95 and Gphn[20-23]. Third, interfering

with postsynaptic protein function in OLs disrupts myelin formation and maintenance[24-25]. And fourth, an OL

precursor cell (OPC)-specific knockout of $GABA_AR$ $\gamma 2$ altered myelin profiles on fast-spiking, GABAergic PV

interneurons and their subsequent firing rate without impacting the myelin or firing rate of neighboring,

glutamatergic spiny stellate cell interneurons[26]. Therefore, OLs and their myelin sheaths are uniquely positioned

to modulate neural circuit output by regulating signal timing and consequently alter the strength or frequency of

circuit signals or eliminate output altogether[27-29]. Thus, we sought to understand whether distinct axon classes

use unique mechanisms for myelination. To this end, we hypothesized that OLs and their individual myelin

sheaths use postsynaptic signaling machinery to coordinate axon identity-dependent myelination.

In this study, we used larval zebrafish to investigate whether Gphn function mediates myelin sheath

formation on specific classes of axons defined by neurotransmitter phenotype. We first used transgenic reporters

for glutamatergic, GABAergic, and glycinergic neurons to show that each neuronal class is myelinated in the

developing spinal cord. Consistent with our hypothesis, Gphn protein localizes to myelin during development

and is enriched in sheaths that wrap GABAergic and glycinergic axons. In the absence of Gphn function, myelin

sheaths that formed on GABAergic axons were abnormally long, whereas sheath lengths were unchanged on

glutamatergic axons. Moreover, with the loss of *gphnb*, overall myelin placement was biased toward

glutamatergic axons and away from GABAergic axons. Together, our work illustrates that Gphn plays an

important role in selecting inhibitory, GABAergic axons for myelination and point to a paradigm where OLs utilize

canonical postsynaptic proteins to establish unique, axon class-specific myelin profiles to coordinate neural

circuit function.

 RESULTS

 Glycinergic, GABAergic, and glutamatergic axons are myelinated in the developing spinal cord

As a first step toward investigating axon class-specific myelination, we examined myelination of larval

zebrafish spinal cord axons defined by neurotransmitter phenotype. To do this, we used combinations of

transgenic reporter genes to simultaneously visualize class-specific axons and myelin. With this approach, we

found that glutamatergic axons (Figure 1A), GABAergic axons (Figure 1B), and glycinergic axons (Figure 1C)

were myelinated. For each neuronal class, myelinated axons occupied both dorsal (Figure 1 orthogonal views

and A',B',C') and ventral spinal cord (Figure 1A'',A''',B'',B''',C'',C'''). Additionally, large myelinated glutamatergic

and glycinergic axons occupied positions near the midline of the spinal cord (Figure 1A'',A''',C'',C'''). Myelinated

GABAergic axons were typically smaller in diameter and occupied more lateral positions (Figure 1B',B''). Thus,

OLs myelinate distinct classes of axons in the dorsal and ventral white matter tracts of the zebrafish larval spinal

cord.

Gephyrin protein localizes to some, but not all, myelin sheaths

OLCs express many genes encoding postsynaptic proteins, some of which appear critical for

myelination[24]. Recent work showed that the postsynaptic scaffold protein Gphn localizes to OPC processes[25]

and OLs continue to express *Gphn* at myelinating stages[20-21]. We predicted that if Gphn mediates axon wrapping

by myelin membrane then it would occupy nascent myelin sheaths. To test this prediction, we used

immunohistochemistry to detect Gphn in transgenic larvae expressing a membrane-tethered myelin reporter

(Extended Data 1A-D). This revealed Gphn localization within myelin in both dorsal (Extended Data 1A',C') and

ventral tracts (Extended Data 1A'',C''). Additionally, we determined that the volume of individual Gphn puncta

and overall punctal density within myelin increased from 4 dpf to 7 dpf (Extended Data 1E,F). These data show

Gphn progressively accumulates in myelin sheaths during development, supporting the notion that Gphn

contributes to myelin sheath formation.

To detect Gphn in living animals, we modified a genetically encoded Gphn intrabody[30] and created a

transgene to analyze the sub-cellular localization in OLs at 4 dpf (Figure 2A, Extended Data 2A, fluorescence)

and 7 dpf (Figure 2B; Extended Data 2B, fluorescence). Like our findings with Gphn immunohistochemistry,

Gphn.FingR puncta per OL increased from 4 dpf to 7 dpf (Figure 2C), an effect that was not influenced by OL

sheath number (Figure 2D). At both 4 dpf and 7 dpf, not all sheaths contained Gphn.FingR signal, therefore, to

examine sub-cellular localization patterns, we quantified the number of Gphn.FingR puncta per sheath. This

showed that individual myelin sheaths had different amounts of Gphn.FingR labeling (Figure 2A'',B''; Extended

Data 2A'',B'', fluorescence), with some sheaths containing a high density of puncta (yellow boxes) and others

with fewer puncta (magenta boxes). the frequency distribution shifted dramatically between 4 and 7 dpf, reflecting

an overall increase in Gphn.FingR expression by 7 dpf (Figure 2E). Notably, some sheaths lacked the Gphn

reporter at both 4 dpf and 7 dpf (Figure 2E). These results show that Gphn differentially accumulates in nascent

myelin sheaths, raising the possibility that it mediates myelination of distinct classes of axons.

Previously, we showed that PSD95, a canonical postsynaptic scaffolding protein at glutamatergic

synapses, localizes to nascent myelin sheaths. Because Gphn localizes to GABAergic and glycinergic synapses,

the presence of these unique scaffolds in specific OLC processes and myelin sheaths[24-25] could provide a

mechanism for selective, axon class-specific myelination. Therefore, to determine whether Gphn and PSD95

occupy the same or different myelin sheaths we examined OLs that simultaneously expressed Gphn and PSD95

intrabodies (Figure 2F,G; Extended Data 2C,D). At 7 dpf, the density of each type of scaffold varied among myelin

sheaths. In particular, some sheaths contained both PSD95 and Gphn puncta, some had more PSD95 puncta

than Gphn puncta (Figure 2F'',G''; Extended Data 2C'',D'', blue boxes), and others had more Gphn puncta than

PSD95 puncta (Figure 2F'',G''; Extended Data 2C'',D'', orange boxes). Altogether, these data indicate that Gphn

and PSD95 are not uniformly distributed among newly formed myelin sheaths. Instead, myelin sheaths contain

different amounts of these scaffold proteins, supporting the possibility that they are equipped to mediate myelin

sheath interactions with distinct axon subtypes.

Myelin on GABAergic and glycinergic axons has more Gphn than myelin on glutamatergic axons

Because Gphn functions at inhibitory neuronal synapses we predicted that it localizes to myelin sheaths

on GABAergic and glycinergic axons. To test this prediction, we investigated Gphn localization within myelin on

glutamatergic, GABAergic, and glycinergic neurons marked by transgenic reporter gene expression (Figure

3A,B,C). We used immunohistochemistry to identify Gphn puncta in myelin on axons corresponding to each

neuronal class (Figure 3A',A'',B',B'',C',C'', yellow arrows), as well as Gphn puncta in myelin on unmarked axons

(blue arrows). This analysis also revealed that some myelin sheaths on specific axonal subtypes lacked Gphn

puncta (magenta arrows). Remarkably, myelin on GABAergic and glycinergic axons contained significantly more

Gphn than myelin on glutamatergic axons (Figure 3D). This further supports our model that postsynaptic proteins

mediate OL interactions with specific classes of axons.

Gphn regulates myelin sheath length

To investigate Gphn function in myelination we created loss-of-function *gphn* mutants using

CRISPR/Cas9 genome editing. Zebrafish have 2 *gphn* paralogs, *gphna* and *gphnb,* likely from an ancestral

genome duplication event[31-32]. By simultaneously targeting *gphna* and *gphnb* we generated 2 lines with mutations

in both genes: *gphna^co91* and *gphnb^co94, and gphna^co92* and *gphnb^co95* (Extended Data 3). Homozygous double

mutant larvae do not survive past 4 dpf, likely due to the role Gphn plays in molybdenum cofactor (MoCO)

biosynthesis throughout the body[33]. We therefore segregated *gphna* and *gphnb* alleles by outcrossing and then

used immunohistochemistry to detect Gphn in larvae with homozygous mutations of each paralog. Whereas

gphna mutant larvae expressed Gphn in the spinal cord, *gphnb* mutant larvae expressed very little (Extended

Data 3D-F). This is consistent with RNA *in situ* hybridization data showing that *gphnb* expression is specific to

the central nervous system in zebrafish, whereas *gphna* is globally expressed[34-35]. These data indicate that that

gphnb mutation mostly eliminates Gphn from the zebrafish nervous system, and we therefore used *gphnb* mutant

larvae for our experiments.

To test whether Gephyrin contributes to myelination, we used *mbpa:eGFP-CAAX* expression to label

individual OLs in *gphnb* mutant and wild-type larvae and analyzed them at different developmental stages (Figure

4A-B). We focused on dorsal OLs because we could assay all sheath characteristics from individual cells. Neither

sheath length nor sheath number differed between homozygous *gphnb* mutant and wild-type larvae at 3 dpf

(Figure 4C-E) or 4 dpf (Figure 4C-E). However, by 7 dpf, myelin sheaths were significantly longer in *gphnb* mutant

larvae than in wild-type larvae (Figure 4C-E). To confirm that this myelin phenotype is due to loss of Gphnb

function and not an off-target mutagenic event, we performed a complementation test using two *gphnb* alleles

derived from independent founders (Extended Data 3G). At 7 dpf, there was no difference in sheath length,

number, or cumulative sheath length between trans-heterozygous *gphnb*[co94/95] mutant larvae and homozygous

gphnb[co95] mutant larvae (Extended Data 3H-J). Together, these data indicate that Gphn limits sheath growth.

Because neurons express Gphn we performed two complementary experiments to test whether myelin

sheath length is limited by Gphn function in OLs. First, we expressed human GPHN in OLs of *gphnb* mutant

larvae using *mbpa:GPHN-2A-mApple-CAAX* (Figure 5A,B). This rescued individual sheath length (Figure 5C)

and cumulative sheath length (Figure 5E), with no change in sheath number (Figure 5D). Second, we expressed

a dominant-negative form of human GPHN, consisting of a single amino acid change (Figure 5F) that disrupts

Nlgn2 and GlyR receptor clustering at inhibitory synapses[36], in OLs of wild-type larvae. Neither sheath number

nor cumulative sheath length were different between wild-type control and dominant-negative expressing OLs

(Figure 5G-H,J-K). However, OL expression of dominant negative GPHN phenocopied the abnormally long

sheaths of *gphnb* mutant larvae (Figure 5I). By comparison, OL expression of wild-type GPHN in wild-type larvae

(Extended Data 4A-B) did not change sheath length, number, or cumulative sheath length compared to controls

(Extended Data 4C-E). Together, these data provide strong evidence that Gphn functions in OLs to mediate

myelin sheath formation.

gphnb mutant larvae are hyperactive, but activity does not determine myelin sheath length

Gphn anchors GABA and glycine receptors at inhibitory neuronal synapses. Because inhibition is critical

to curtail excitatory output, we predicted that *gphnb* mutant larvae would be hyperactive as a result from reduced

inhibition of locomotive circuits. Therefore, we tracked swimming behavior, and at 7 dpf (Figure 6A), *gphnb*

mutant larvae covered more distance (Figure 6B), and swam at increased velocity compared to wild-type control

larvae (Figure 6C). Because neuronal activity promotes myelination[15,18-19,37-47] we tested the possibility that

neuronal activity drives formation of long myelin sheaths in *gphnb* mutant larvae. To do this, we blocked neuronal

activity using tetrodotoxin (TTX), which inhibits voltage-gated sodium channels. We injected TTX or a control

solution into the yolk sac and selected paralyzed fish in the TTX group for imaging at 7 dpf (Figure 6D). In wild-

type larvae, TTX-induced silencing reduced sheath number and increased individual sheath length, with no

change in cumulative length (Figure 6E-F, I-K). By contrast, TTX-induced silencing did not change sheath

number, length, or cumulative length in *gphnb* mutant larvae relative to controls (Figure 6G-H, I-K). We conclude

that the excessively long myelin sheaths of *gphnb* mutant larvae do not result from elevated neuronal activity.

Additionally, these data raise the possibility that loss of Gphn function impairs neuronal activity-dependent

modulation of myelin sheath characteristics.

Gphn limits myelin sheath length on GABAergic axons and biases them for myelination over

glutamatergic axons

In neurons, Gphn functions specifically at synapses that engage in GABAergic and glycinergic signaling.

Could Gphn function similarly in nascent myelin sheaths to mediate specific interactions with GABAergic and

glycinergic axons? To test this, we used transgenic reporters to determine whether the sheath length phenotype

of *gphnb* mutant larvae is specific to axon class (Figure 7A-D). In wild-type larvae, there was no difference

between sheath lengths on glutamatergic and GABAergic axons (Figure 7E). By contrast, myelin sheaths were

longer on GABAergic axons than on glutamatergic axons in *gphnb* mutant larvae (Figure 7E). Additionally, there

was no difference in the lengths of myelin sheaths formed by individual OLs on GABAergic axons and all other,

unlabeled, axons in wild-type larvae (Figure 7F, teal), whereas in *gphnb* mutant larvae the long myelin sheaths

of individual OLs were placed on GABAergic axons rather than other, non-labeled axons (Figure 7F, purple).

Furthermore, in wild-type larvae the myelin sheaths on glutamatergic axons were slightly longer than those on

other axons (Figure 7G, orange), but this difference was absent in *gphnb* mutant larvae (Figure 7G, gray).

Together, these data indicate that for individual *gphnb* mutant OLs, long sheaths more frequently occupy

GABAergic axons, suggesting an axon class-specific role for Gphn in regulating myelin sheath length.

Finally, we examined whether Gphn influences which axons are myelinated. Quantification of myelinated

glutamatergic (Figure 8A,B) and GABAergic axons (Figure 8C,D) in transverse spinal cord sections showed that

gphnb mutant larvae had more myelinated glutamatergic axons and fewer myelinated GABAergic axons

compared to wild-type control larvae (Figure 8E). These differences were evident in both dorsal (Figure 8F) and

ventral spinal cord (Figure 8H), but not among medially myelinated axons (Figure 8G). Notably, there was no

difference in the total volume of myelin or myelin volume of dorsal, ventral, or medial myelin between *gphnb*

mutant and wild-type larvae (Extended Data 5A-D). These results indicate that the loss of *gphnb* function shifts

myelin placement onto glutamatergic axons from GABAergic axons without changing the total amount of myelin.

Collectively, we interpret these data to mean that Gphn both biases GABAergic axons for myelination and limits

the length of myelin sheaths that form on them, indicating a neurotransmitter identity-dependent function for

Gphn in myelination.

DISCUSSION

OLs can myelinate fixed axons and synthetic substrates in vitro[48-50], indicating that OLs can myelinate axons

without the need for specific molecular or cellular cues that distinguish them. However, not all axons are

myelinated in vivo and different types of axons are covered by distinct patterns of myelin[10-14]. Furthermore, OLs

preferentially place myelin on axons that are more electrically active[15,18-19,43-44,46-47]. These observations suggest

that OLs can discriminate between the many different types of axons they encounter in a developing nervous

system, but the mechanisms by which they do so remain unknown. In this study, we sought to understand

whether OLs use unique molecular machinery to selectively myelinate axons of distinct neurotransmitter classes.

Building on prior evidence that synaptic-like mechanisms promote myelin sheath formation, we focused our

investigation on Gphn, a scaffolding protein that functions at neuronal postsynaptic terminals that receive

inhibitory signals. Altogether, our data support a model where myelinating OLs repurpose classical postsynaptic

machinery to facilitate myelination of unique axon classes with specificity characteristic of neuronal synapses

(Extended Data 6).

Electrophysiological measurements revealed that neurons make glutamatergic and GABAergic synaptic

connections with OL precursor cells (OPCs), which can mediate excitable responses within OPCs[51-56]. Strikingly,

calcium activity in OPC processes correlated with Gphn localization, preceding and predicting which processes

eventually formed myelin sheaths[25]. Thus, neuronal activity might convey pro-myelinating signals to OPCs via

Gphn-mediated synaptic interactions. Whether synaptic mechanisms also mediate axon-OL interactions during

myelin sheath formation has been unclear. Although electrical activity was not detected in OLs[57], activity-

dependent calcium transients were evident in nascent myelin sheaths[58-59]. OLs express genes that encode

postsynaptic proteins following their differentiation from OPCs[20-21] and our prior work[24], together with data we

present here, show that the postsynaptic proteins Cadm1b, Caska, PSD95, and Gphn occupy nascent myelin

sheaths in zebrafish. Thus, newly differentiating OLs might have the capacity to interact with presynaptic

molecules displayed on axons during myelin sheath formation.

Neurons use different molecular complexes to assemble different types of synapses, particularly excitatory

and inhibitory synapses. These complexes, anchored by the scaffold proteins Gphn at inhibitory synapses, and

PSD95 at excitatory synapses, are necessary for the specificity of neurotransmission. Neurons receive both

inhibitory and excitatory inputs by segregating these molecular complexes to different postsynaptic terminals.

Consistent with prior observations using mice[12-14], we determined that OLs myelinate inhibitory GABAergic and

glycinergic axons as well as excitatory glutamatergic axons in the zebrafish spinal cord. Remarkably,

simultaneous observation of PSD95 and Gphn using intrabodies revealed that they frequently are concentrated

in different myelin sheaths of individuals OLs. Moreover, we determined that myelin on GABAergic and

glycinergic axons has more Gphn than myelin on glutamatergic axons. These observations raise the intriguing

possibility that, similar to neurons, distinct postsynaptic complexes within individual myelin sheaths facilitate

interaction with specific types of axons. How then do OLs use postsynaptic factors for myelin sheath formation?

Here we learned that in the absence of Gphn function, the myelin sheaths that wrapped GABAergic axons were

abnormally long whereas myelin sheaths on glutamatergic axons were unaffected. This effect on sheath length

was only evident at 7 dpf, after myelin sheath extension is normally complete in the spinal cord of larval

zebrafish[60]. Prior investigations also revealed that disruptions of postsynaptic protein functions have

consequences for myelin sheath formation. For example, we showed that OL-specific expression of dominant

negative forms of the synaptogenic adhesion proteins Nlgn2b, Cadm1b, and Lrrtm1 caused either longer

(Nlgn2b) or shorter (Cadm1b, Lrrtm1) myelin sheaths[24]. Using a transient, cell-type specific CRISPR/Cas9

mutagenesis approach, Li et al. found that knockdown of *dlg4a/b*, which encode PSD95, g*phnb*, and *nlgn3b* in

zebrafish reduced the total length of myelin sheaths at 5 dpf[25]. Finally, an OLC-specific γ2-GABA$_A$ receptor

subunit knock-out resulted in long myelin sheaths in the mouse barrel cortex[26]. This effect was evident on

inhibitory, GABAergic parvalbumin (PV)+ interneurons, while neighboring excitatory, glutamatergic spiny stellate

cells (SSC) retained normal myelin. Notably, none of these functional manipulations prevented myelination, but

they consistently altered myelin sheath length. Neuronal activity also can modulate sheath length[18,43-44], and

sheath length can influence neuronal firing patterns[27-29,61-62]. Thus, postsynaptic proteins expressed by OLs might

be key mediators of myelin plasticity, similar to their roles in synaptic plasticity. In support of this possibility, we

found that in *gphnb* mutant larvae, myelin sheaths were unresponsive to TTX-mediated inhibition of neuronal

activity as they are in wild-type larvae.

Perhaps our most striking finding is that the absence of Gphn function causes myelin sheaths to wrap

GABAergic axons less frequently and glutamatergic axons more frequently, without changing the total amount

of myelin. With our observation that Gphn is enriched in myelin on GABAergic axons relative to myelin on

glutamatergic axons, this suggests that Gphn biases myelination for inhibitory axons, potentially providing a

mechanistic explanation for a prior observation that some OLs preferentially myelinate inhibitory axons in the

mouse cortex[14]. Together, these results point to a model where postsynaptic proteins function to aid myelin

targeting and formation on distinct classes of axons.

An important limitation to our study is that our *gphnb* mutant alleles affect Gphn function throughout the

animal. Thus, inhibitory synaptic function likely is impaired in *gphnb* mutant larvae, which could affect

myelination. However, our data from several complementary experiments provide strong evidence to support an

autonomous role for Gphn in OLs in the process of myelination. A more rigorous approach will require

development of a robust and verifiable transgenic method for efficiently eliminating Gphn from OLs. We are

currently unable to determine the functional consequences of abnormal myelin caused by OL-specific loss of

Gphn. Again, this will require a system for OL-specific mutagenesis.

Collectively, our data reveal a role for canonical postsynaptic proteins in myelination of specific

neurotransmitter axon classes. We provide evidence that Gphn biases selection of inhibitory axons for myelin

targeting and influences myelin sheath growth. Because myelin can alter axonal conduction velocity[27-29], myelin

targeting and plasticity can provide a powerful influence on circuit development by fine tuning the activity of

individual axons within developing neural circuits[63-65]. This is supported by evidence where the specific loss of

the γ2-GABA$_A$ subunit in OLCs disrupted PV+ firing rate without altering neighboring excitatory SSC frequency[26].

Consequently, the redistribution of myelin patterns on specific axon classes we find in *gphnb* mutant larvae could

have important consequences for neural circuit function by disrupting the balance of excitatory and inhibitory

signaling (E/I balance)[62-68]. This raises the possibility that genetic variants of synaptic genes that are significantly

linked to neuropsychiatric disorders, such as autism and schizophrenia, alter myelination, thereby contributing

to the E/I imbalance characteristic of those diseases.

 FIGURES

Figure 1. Glycinergic, GABAergic, and glutamatergic axons are myelinated in the developing spinal cord. Representative images of transverse spinal cord sections of 4 dpf larvae expressing the transgene *Tg(sox10:mRFP)* (myelin, purple) along with *Tg(slc17a6:eGFP)* (glutamatergic axons, green, A); *Tg(gad1b:eGFP)* (GABAergic axons, green, B); or *Tg(slc6a5:eGFP)* (glycinergic axons, green, C). (A'-C''') Magnification of boxed regions showing individual myelinated axons; (A'-C') orthogonal views show *sox10*:mRFP⁺ myelin sheaths on a dorsal *slc17a6*:eGFP⁺ glutamatergic axon (A'), a *gad1b*:eGFP⁺ GABAergic axon (B'), and a *slc6a5*:eGFP⁺ glycinergic axon (C'). Magnified transverse views of *sox10*:mRFP⁺ myelin surrounding *slc6a5*:eGFP⁺ glutamatergic axons (A'-A''), *gad1b*:eGFP⁺ GABAergic axons (B'-B''), and *slc6a5*:eGFP⁺ glycinergic axons (C'-C''') in the ventral spinal cord. Yellow arrows indicate myelinated axons in enlarged panels. A-C scale bars = 5 μm. Zoom scale bars = 2 μm.

Figure 2. Variable localization of Gphn and PSD95 in myelin sheaths during development. Three dimensional surface models of individual OLs expressing a genetically encoded Gphn intrabody (*zfmbpa:*Gphn.FingR-mScarlet-IL2RGTC-KRAB(A), orange) within *mbpa:*eGFP-CAAX membranes (purple) at 4 dpf (A-A'') and 7 dpf (B-B''). Yellow boxes indicate an individual myelin sheath with abundant Gphn intrabody signal, while magenta boxed regions indicate an individual sheath with little Gphn intrabody signal. Quantification of Gphn puncta counts per OL (C; 4 dpf mean = 500±246, 7 dpf mean = 1371±685; Wilcoxon rank sum test) and sheath number per OL (D; 4 dpf mean = 17.5±5.09, 7 dpf mean = 14.1±5.17; Student's T-Test), at 4 dpf and 7 dpf. p<0.05 is considered significant. (E) Frequency distribution of Gphn puncta per sheath at 4 dpf (orange, n = 11 OLs and larvae) and 7 dpf (purple, n = 10 OLs and larvae), with a dashed line representing the mean (4 dpf mean = 28.5±20.7, 7 dpf mean = 97.2±83.5). (F-G) Surface model of two OLs expressing *mbpa:*tagBFP-CAAX (purple), Gphn intrabody (orange), and the PSD95 intrabody *zfmbpa:*PSD95.FingR-eGFP-CC5TC-KRAB(A) (cyan) at 7 dpf.

317   Cyan boxes highlight sheaths with stronger PSD95 signal, and orange boxes denote sheaths with robust Gphn signal. Scale
318   bars = 5 μm.
319
320

321
Figure 3. Enrichment of Gphn protein in myelin on GABAergic and glycinergic axons. Representative transverse
images of a *Tg(slc17a6:eGFP); Tg(mbp:mCherry-CAAX)* larva (A) *Tg(gad1b:mScarlet-CAAX); Tg(mbp:eGFP-CAAX)* larva
(B), and a *Tg(slc6a5:eGFP); Tg(mbp:mCherry-CAAX)* larva (C) processed to detect Gphn at 7 dpf. (A' and A'') Magnified
panels of boxed regions in A indicating Gphn puncta (orange) in myelin (purple) on glutamatergic axons (green). (B' and B'')
Magnification of boxed regions in B indicating Gphn puncta in myelin on GABAergic axons (cyan). (C' and C'') Magnification
of boxed regions in A indicating Gphn puncta in myelin on glycinergic axons (green). In all magnifications, yellow arrows
point to Gphn puncta in myelin on the labeled axon class, cyan arrows point to Gphn puncta in myelin not on the labeled
axon class, and magenta arrows point to myelin on the labeled axon class without Gphn puncta. (D) Quantification of the
percent of Gphn puncta in myelin wrapping each axon class, using the Kruskal-Wallis test for global significance followed
by Bonferroni-corrected Wilcoxon multiple comparisons (glutamatergic mean = 24.4%±5.33, GABAergic mean =
40.6%±5.33, glycinergic mean = 39.9%±6.31). p<0.05 is considered significant. All groups n = 11 larvae. Scale bars = 5 μm,
zoom panel scale bars = 1 μm.
334

335
Figure 4. Progressive increase in myelin sheath length in *gphnb* mutant larvae over development. Representative
images of mosaically labeled OLs of wild-type (A) and *gphnb* mutant (B) larvae at 7 dpf. Statistical comparisons of sheath
characteristics at 3 dpf, 4 dpf, and 7 dpf in wild-type (teal) and *gphnb* mutant (purple) larvae, including individual sheath
length (C; 3 dpf, wildtype mean = 28.8 μm±13.6, *gphnb* mean = 29.0 μm±14.0; 4 dpf, wildtype mean = 35.3μm±14.7, *gphnb*
mean = 37.7 μm±16.2; 7 dpf, wildtype mean = 39.1μm±16.1, *gphnb* mean = 42.6μm±17.0) total sheaths per cell (D; 3 dpf,
wildtype mean = 13.1±3.84, *gphnb* mean = 13.4±3.99; 4 dpf, wildtype mean = 16.1±3.45, *gphnb* mean = 14±4.99; 7 dpf,
wildtype mean = 13.1±4.80, *gphnb* mean = 15.4±5.49), and cumulative sheath length per OL (E; 3 dpf, wildtype mean =
376 μm±87.4, *gphnb* mean = 389 μm±98.6; 4 dpf, wildtype mean = 567 μm±117, *gphnb* mean = 528 μm±135; 7dpf, wildtype
mean = 513 μm±117, *gphnb* mean = 657 μm±221). 3 dpf: wildtype n = 13 OLs and larvae, *gphnb* n = 30; 4 dpf: wildtype n
= 15, *gphnb* n = 18; 7 dpf: wildtype n = 16, *gphnb* n = 21; significance determined by a Type-III sum of squares test followed
by Bonferroni-corrected multiple comparisons. p<0.05 is considered significant. Scale bars = 10 μm.
347

348
Figure 5. Oligodendrocyte-specific requirements for Gephyrin in myelination. Representative images of individual
OLs in *gphnb* mutant larvae expressing control construct *mbpa:*mApple-CAAX (A) and *mbpa:*GPHN-2a-mApple-CAAX (B)
at 7 dpf. Quantification of individual sheath length (C; *gphnb* mean = 50.2μm±19.3, rescue mean = 42.1μm±15.7), sheaths
per OL (D; *gphnb* mean = 15.6±5.42, rescue mean = 13.6±4.42), and cumulative sheath length per cell (E; *gphnb* mean =
780μm±261, rescue mean = 572μm±104) in 7 dpf larvae. (F) Schematic representing the location (orange bar) and amino
acid change in a dominant negative construct adapted from Kim et al., 2021. Example images of OLs in wild-type expressing
control plasmid *mbpa:*mApple-CAAX (G) and the dominant negative Gphn construct *mbpa:*dnGPHN-2a-mApple-CAAX (H)
at 7 dpf. Quantification of individual sheath length (I; wildtype mean = 38.1μm±15.7, dominant negative mean =
40.7μm±14.6), sheaths per OL (J; wildtype mean = 18.3±5.41, dominant negative mean = 14.7±5.64), and cumulative
sheath length per cell (K; wildtype mean = 699μm±223, dominant negative mean = 600μm±198). (A-E) *gphnb* mutant = 16
OLs and larvae, *gphnb* +GPHN = 17; (G-K) wildtype control = 15; wildtype +dnGPHN n = 19. (C, E, and I) statistical
comparisons were performed with the Wilcoxon rank sum test; (D, J, and K) statistical comparisons were performed with
the Student's T-Test; p<0.05 is considered significant. Scale bars = 10 μm.
362

363
Figure 6. *gphnb* mutant hyperactivity does not account for long myelin sheaths. (A) Tracking data from a behavioral
trial with 6 wild-type (left, boxed in teal) and 6 *gphnb* mutant (right, boxed in purple) at 7 dpf. Red lines are traces of the
swimming path of an individual larva during the 10 minute video recording. Quantification of cumulative distance swam (B;
wildtype mean = , *gphnb* mean =) and swimming velocity (C; wildtype mean = , *gphnb* mean =). (D) Experimental timeline
for tetrodotoxin (TTX) experiments: 1) mosaic expression of *mbpa:*eGFP-CAAX at the single-cell stage; 2) eGFP sorting
and TTX or control injections at 6 dpf; 3) confocal imaging at 7 dpf. Representative images of OLs in wild-type control (E),
wild-type +TTX (F), *gphnb* mutant control (G), and *gphnb* +TTX (H) conditions. Quantification of sheaths per OL (I; wildtype
control mean = 16.2±5.14, wildtype TTX mean = 12.2±2.67, *gphnb* control mean = 14.9±3.85, *gphnb* TTX mean =
14.7±5.48), individual sheath length (J; wildtype control mean = 39.3 μm±16.1, wildtype TTX mean = 49.2 μm±19.7, *gphnb*
control mean = 46.2 μm±18.1, *gphnb* TTX mean = 48.2 μm±18.9), and cumulative sheath length (K; wildtype control mean

= 636 μm $\pm$106, wildtype TTX mean = 598 μm $\pm$159, *gphnb* control mean = 690 μm $\pm$194, *gphnb* TTX mean = 708 μm $\pm$237).
B and C comparisons performed with Wilcoxon rank sum tests; wild-type n = 60 larvae; *gphnb* mutant n = 84. I and J
comparisons performed with Wilcoxon rank sum tests; K comparisons with unpaired student's t-tests; wildtype control n =
17; wildtype +TTX n = 13; *gphnb* control n = 14; *gphnb* +TTX n = 13. p<0.05 is considered significant. Scale bars = 10 μm.

378
379 **Figure 7. Myelin sheaths are selectively longer on GABAergic axons in *gphnb* mutant larvae.** (A-A'') Representative
380 images of individual OLs mosaically labeled with *mbpa:*mApple-CAAX (purple) in a *Tg(slc17a6:eGFP)* (green) glutamatergic
381 wildtype larva (A-A''), and *gphnb* mutant (B-B''); and *Tg(gad1b:eGFP)* GABAergic wildtype larva (C-C''), and *gphnb* mutant

(D'-D") at 7 dpf. Yellow arrows point to the edges of an individual myelin sheath that wraps the labeled axon class, and cyan arrows point to the edges of an individual myelin sheath that does not wrap the labeled axon class. (E-F) Sheath length quantification of individual sheaths that wrap the labeled axon class between wildtype (teal) and *gphnb* mutants (purple) (E), and comparison of sheath length between axon class (light purple GABAergic, dark purple glutamatergic) within genotypes. (G-H) Comparison of individual sheath length between sheaths that wrap the labeled class and sheaths that don't wrap the labeled class for GABAergic axons (G) and glutamatergic axons (H). (E) statistical comparisons were performed with the Wilcoxon rank sum test (wildtype GABAergic mean = 36.5 μm$\pm$16.3, wildtype glutamatergic mean = 38.7 μm $\pm$17.4, *gphnb* GABAergic mean = 43.9 μm $\pm$14.1, *gphnb* glutamatergic mean = 37.6 μm $\pm$15.2). (F, G) significance determined by a Type-III sum of squares test followed by Bonferroni-corrected multiple comparisons (F, GABAergic: wildtype on axon mean = 36.5 μm $\pm$16.3, wildtype on other axon mean = 32.4 μm $\pm$13.5, *gphnb* on axon mean = 43.9 μm $\pm$14.1, *gphnb* on other axon mean = 36.2 μm $\pm$12.7; G, glutamatergic: wildtype on axon mean = 38.7 μm $\pm$17.4, wildtype on other axon mean = 34.0 μm $\pm$13.5, *gphnb* on axon mean = 37.6 μm $\pm$15.2, *gphnb* on other axon mean = 35.3 μm $\pm$14.6). p<0.05 is considered significant; wildtype glutamatergic n = 10 OLs and larvae; *gphnb* glutamatergic n = 10; wildtype GABAergic n = 12; *gphnb* GABAergic n = 9. Scale bars = 5μm.

397
Figure 8. Loss of *gphnb* biases myelin formation onto glutamatergic axons. Representative images of glutamatergic
neurons (*TgBAC(slc17a6:eGFP)*, green) and myelin (*Tg(sox10:mRFP)*, purple) transgenic reporters in wildtype (A) and
gphnb (B) larvae, and GABAergic neurons (*TgBAC(gad1b:eGFP)*, green) and myelin transgenic reporters in wildtype (C)
and *gphnb* (D) larvae at 7 dpf. Magnified regions boxed in yellow are enlarged to show dorsal (1) and ventral (2, 3) regions

in detail. Yellow arrows point to myelinated axons in magnified panels. Quantification of myelinated axon counts for a single
side of the spinal cord for total myelinated axons (E; wildtype GABAergic mean = 84.8±6.39, *gphnb* GABAergic mean =
75.9±3.30, wildtype glutamatergic mean = 99.6±7.26, *gphnb* glutamatergic mean = 111±7.38), dorsal myelinated axons (F;
wildtype GABAergic mean = 31.5±3.27, *gphnb* GABAergic mean = 25.6±1.07, wildtype glutamatergic mean = 22.8±2.57,
gphnb glutamatergic mean = 27.1±3.66), medial myelinated axons (G; wildtype GABAergic mean = 16.2±3.20, *gphnb*
GABAergic mean = 17.3±2.56, wildtype glutamatergic mean = 7.04±3.23, *gphnb* glutamatergic mean = 9.29±2.50), and
ventral myelinated axons (H; wildtype GABAergic mean = 37.1±3.21, *gphnb* GABAergic mean = 33.0±1.66, wildtype
glutamatergic mean = 69.8±5.56, *gphnb* glutamatergic mean = 74.8±3.93). Significance was determined with the Student's
T-Test for E and G, and the Wilcoxon rank sum test for F and H. $p < 0.05$ is considered significant. All groups n = 8 larvae.
Scale bars = 5 μm. Magnified panel scale bars = 2 μm.

Extended Data 1. Gephyrin protein localizes to myelin sheaths during development. (A-D) Representative images of the spinal cord in *Tg(mbpa:eGFP-CAAX)* (purple) larvae immunostained for Gphn (green). (A) 4 dpf larva. (A') Magnification of boxed region in A showing Gphn puncta in dorsal myelin. (A'') Magnification of boxed region in A of Gphn puncta in ventral myelin. B) 20 μm fluorescent stack of same larva in A. (B') Surface reconstruction of stack in B of myelin and Gphn puncta contained to myelin channel. (C) 7 dpf larva. (C') Magnification of boxed regions in C of Gphn puncta in dorsal myelin (C') and ventral myelin (C''). (D) 20 μm fluorescent stack of same larva in C. (D') Surface reconstruction of stack in D of myelin and Gphn puncta filtered by distance to myelin channel ≤ 0 μm. Yellow arrows denote Gphn puncta in myelin. (E) Quantification of the mean Gphn puncta in myelin per 100 μm^3 at 4 dpf (mean = 0.007±0.002) and 7 dpf (mean = 0.011±0.005). (F) Quantification of the mean Gphn punctal volume (μm^3) in myelin at 4 dpf (mean = 0.062 μm^3±0.122) and 7 dpf (mean = 0.102 μm^3±0.201). Data were compared with unpaired student's t-tests, where p<0.05 is considered significant; 4dpf n = 5 larvae, 7 dpf n = 11 larvae. A-D scale bars = 5 μm; magnified scale bars = 1 μm.

Extended Data 2. Detection of Gphn and PSD95 in OLs of living larvae using intrabodies. (A) Fluorescent images of the individual OLs expressing *mbpa:*eGFP-CAAX (myelin sheaths, purple, A') and a genetically encoded Gphn intrabody (orange, A'') at 4 dpf and 7 dpf (B-B''). Yellow boxes indicate an individual myelin sheath with abundant Gphn intrabody signal, while magenta boxed regions indicate an individual sheath with little Gphn intrabody signal. (C and D) Fluorescent images of the two OLs in Figure 2E-F, labeled with *mbpa:*tagBFP-CAAX (purple), Gphn intrabody (orange), and PSD95 intrabody (cyan). Cyan boxes indicate individual sheaths with strong PSD95 signal and orange boxes indicate myelin sheaths with robust Gphn signal. Scale bars = 5 μm.

Extended Data 3. Generation and validation of *gphna^co92* and *gphnb^co95* mutant zebrafish. (A) Schematics of genomic
sequences for *gphna* and *gphnb*. Exon 1 is enlarged to show where gRNAs align (black bars), and Exon 1 sequence is
listed with gRNA sequence (bold and underlined) below the corresponding reverse complement genomic sequence (green)
and PAM site (bold and underlined). (B) Sequence changes in exon 1 for *gphna^co92* (13 bp deletion) and *gphnb^co95* (4 bp
deletion plus 29 bp insertion) alleles. The lighter shaded region between black bars in the wildtype indicates the sequence

deleted in the mutants, and the orange region indicates the insertion for the *gphnb*[co95] allele. (C) Gphn protein domain
structure with the C domain, G domain, and E domains indicated. Below are schematic representations of the amino acid
consequence of the *gphna*[co92] allele (6 missense amino acids followed by a premature stop codon), and the *gphnb*[co95] allele
(18 total missense amino acids and a premature stop codon), with altered amino acid regions indicated in orange. (D)
Representative images of transverse sections of the spinal cord using immunohistochemistry to detect Gphn in wild-type,
gphna[co92], and *gphnb*[co95] larvae at 7 dpf. (E) Quantification of the mean Gphn puncta per 100 μm^3 volume in D (wildtype
mean = 20.5±4.62, *gphnb* mean = 8.00±7.32; *gphna* mean = 24.7±5.39). (F) Quantification of the mean Gphn puncta volume
(μm^3) in D (wildtype mean = 0.023 μm^3±0.002, *gphnb* mean = 0.014 μm^3±0.002; *gphna* mean = 0.053 μm^3±0.008). (E-F) n
= 12 larvae each for wildtype, *gphna*[co92] and *gphnb*[co95]; Kruskal-Wallis test was used for non-parametric global comparison
followed by Bonferroni-corrected T-Test comparisons). (G) Example images of individual dorsal OLs for *gphnb*
complementation test with *gphnb*[co95] and *gphnb*[co94/co95] larvae at 7dpf. Quantification of sheath length (H; *gphnb*[co95] mean =
53.8 μm±19.7, *gphnb*[co94/co95] mean = 51.1 μm±19.1), sheaths per cell (I; *gphnb*[co95] mean = 14±3.66, *gphnb*[co94/co95] mean =
15.8±2.79), and cumulative sheath length (J; *gphnb*[co95] mean = 753 μm±202, *gphnb*[co94/co95] mean = 808 μm±104) for
gphnb[co95] (n = 15 larvae), and *gphnb*[co94/co95] (n = 11 larvae). Statistical comparisons with Wilcoxon rank sum test (H) and
the student's T-Test (I and J). p<0.05 is considered significant. Scale bars: D = 5 μm; G = 10 μm.
456
457

mbpa:mApple-CAAX

*mbpa:*GPHN-2A-mApple-CAAX

458
459 **Extended Data 4. Oligodendrocyte-specific overexpression of human GPHN does not influence myelination in wild-**
460 **type larvae.** Representative images of individual OLs in wild-type larvae expressing control construct *mbpa:*mApple-CAAX
461 (A) and overexpressing GPHN *mbpa:*GPHN-2A-mApple-CAAX (B) at 7 dpf. Statistical comparisons of myelin sheath
462 characteristics in control (teal) and GPHN overexpression (orange), including individual sheath length (C; control mean =
463 41.2μm±14.7, overexpression mean = 42.7μm±12.0), total sheath count per cell (D; control mean = 14.2±4.09,
464 overexpression mean = 14.5±5.04), and cumulative sheath length per cell (E; control mean = 584μm±154, overexpression
465 mean = 621μm±193). Comparisons were performed with a Wilcoxon rank sum test (C) and unpaired student's t-tests (D
466 and E), where p<0.05 is considered significant; control n = 13 OLs and larvae; overexpression n = 13. Scale bars = 10 μm.

467
Extended Data 5. Total myelin volume is unchanged in *gphnb* mutant larvae. Representative images of wild-type (A,
A') and *gphnb* mutant (B, B') *Tg(mbpa:eGFP-CAAX)* larvae at 7 dpf, including fluorescence projections (A, B) and three-
dimensional surface models (A', B'), with myelin labeled in distinct regions: dorsal (purple), medial (cyan), and ventral
(orange). Statistical comparisons of myelin volume at 7 dpf, including mean total myelin volume per 100 μm^3 in wild-type
(teal) and *gphnb* (purple) mutant larvae (C; wildtype mean = 2.23 μm^3±1.70, *gphnb* mean = 2.04 μm^3±0.343), and mean
myelin volume in dorsal, medial, and ventral spinal cord regions (D; dorsal, wildtype mean = 0.405 μm^3±0.289, *gphnb* mean
= 0.433 μm^3±0.127; medial, wildtype mean = 0.0567 μm^3±0.0505, *gphnb* mean = 0.0701 μm^3±0.0361; ventral, wildtype
mean = 1.77 μm^3±1.41, *gphnb* mean = 1.54 μm^3±0.262). wildtype n = 14 larvae, *gphnb* = 13 larvae; C and D statistical
comparisons were performed with unpaired Student's T-tests, aside from medial myelin (Wilcoxon rank sum test). p<0.05
is considered significant. Scale bars = 5 μm.
478

479
480 **Extended Data 6. Working model of Gphn function in oligodendrocytes in axon identity-dependent myelination.** (A)
481 Gphn localizes to myelin sheaths that wrap GABAergic and glycinergic axons. (B) In the absence of *gphnb*, more
482 glutamatergic axons are myelinated, fewer GABAergic axons are myelinated (blue arrows), and the myelin sheaths that
483 remains on GABAergic axons are longer (dashed line).
484

MATERIALS AND METHODS

Zebrafish Lines and Husbandry. All fish and larvae were handled in accordance with the University of Colorado Institutional Animal Care and Use Committee (IACUC). Previously generated transgenic lines used in this manuscript included: *TgBAC(slc17a6b:eGFP)*[69-70]; *Tg(slc6a5:eGFP)*[71]; *TgBAC(gad1b:eGFP)*[72]; *Tg(sox10:mRFP)*[vu234],[73]; *Tg(mbpa:eGFP-CAAX)*[co58],[74-75]; and *Tg2(mbpa:mCherry-CAAX)*[co13],[69]; see key resources table for Zfin IDs). After egg collection or injections, embryos were stored at 28.5°C in petri dishes at a density of roughly 60 embryos per plate or less in egg water (6g instant ocean in 20L miliQ water). Larvae hatched from chorions were stored at similar density in screen media (1X E3, 60μg/mL NaHCO₃, 145μg/mL CaCl₂) up to 7 days post fertilization (dpf). For embryo injections, eggs were collected within 30 min of breeding and injected at the single-cell stage. For Tol2 transgenesis injections, 6-25 ng/mL of expression plasmids were injected in 2-3 nL drops. Larvae were then screened prior to imaging for transgenesis reporters or fluorescent protein expression in the spinal cord. When animals for fixed experiments needed genotyping, larvae were anesthetized and quickly tail clipped, and the body was fixed in 4% paraformaldehyde (PFA) while the tail was lysed and used for genotyping. Otherwise, larvae for fixed experiments were euthanized with 4% Tricaine mesylate prior to fixation.

Mutagenesis. We used the CRISPR/Cas9 system to generate our *gphn* loss-of-function mutations. We used CRISPOR[76] to design guide RNAs that target the coding sequence of exon 1 for both *gphna* and *gphnb* (figure 5, see key resources table for gRNA sequences). We followed the "Alt-R CRISPR-Cas9 System: *In vitro* cleavage of target DNA with ribonucleoprotein complex" protocol to synthesize each gRNA (http://sfvideo.blob.core.windows.net/sitefinity/docs/default-source/protocol/alt-r-crispr-cas9-protocol-in-vitro-cleavage-of-target-dna-with-rnp-complex.pdf?sfvrsn=88c43107_2, 2017). The RNP complex was created immediately prior to injections with 0.5 μg final concentration of Cas9 (IDT) diluted in Cas9 working buffer (20 mM HEPES, 150 mM KCL, pH7.5), 100 ng each of *gphna* and *gphnb* gRNAs, and incubated at 37°C for 10 min. This solution was then kept at room temperature until injected, with *gphna* and *gphnb* guides co-injected into wild-type embryos with 2-3 nL at the single-cell stage to generate double mutants. Several F0 injected larvae were screened for evidence of insertions and deletions created by DNA cutting and repair with PCR primers that

span the guide target site (see key resources table for primers and sequences). F0 larvae were grown to

adulthood and individually outcrossed to wild-type fish. Individual F1 larvae were anesthetized and 50 mM NaOH

was used for genomic DNA extraction followed by 1M Tris, pH9 neutralization. Mutant allele identification was

performed on several individual F1 animals from at least two unique F0 founders each via TA cloning and

sequencing followed by alignment with the published genome. F1 adults carrying selected $gphna^{co91}$, $gphna^{co92}$,

$gphnb^{co94}$, and $gphnb^{co95}$ mutant alleles were then outcrossed and F2 generation larvae grown for experiments.

All wildtype and mutant larvae used for mutant experiments were genotyped to confirm alleles.

Behavior. Individual larvae were placed into single wells in a 24-well plate at 7 dpf and given an equal volume

of screen media per well. Larvae in 24-well plates were then transferred to the CU Anschutz behavior core in a

covered box and allowed to acclimate to the room for 10 min. For the behavior recording, the plate was placed

in the DanioVision (Noldus) recording box and larvae were allowed to habituate to the box for 10 min prior to

recording start. Larvae were then recorded for 10 min. Following behavior, larvae were anesthetized and lysed

for genotyping.

TTX Injections. For neuronal activity experiments, the voltage-gated sodium channel blocker tetrodotoxin (TTX)

was injected into the yolk sac at 6 dpf. All animals were anesthetized with Tricaine and sorted for fluorescent

reporter expression stereomicroscope equipped with epifluorescence optics. While anesthetized, larvae were

then placed into molds made of 2% agarose in egg water with individual larval wells. Larvae were positioned in

the wells such that their yolk sacs faced up, and 3-4 nL buffered TTX (0.6 mM TTX, 0.4 M KCL, 0.05% phenol

red, and water) or control solution (0.4 M KCL, 0.05% phenol red, and water) was injected into the yolk sac below

the swim bladder. Animals were then removed from the molds and placed into fresh egg water and allowed to

recover fully for 24 hrs prior to imaging.

Cloning. Several plasmids, listed in the key resources table, were generated using the Gateway system and the

Tol2 kit[77]. To create the Gephyrin intrabody middle entry vector we used *pCAG_GPHN.FingR-mKate2-IL2RGTC*

(Addgene plasmid #46297; RRID: Addgene_46297) and replaced the mKate2 fluorophore with mScarlet *in silico*.

Using this plasmid as a template, we custom ordered *pEXPR-zfmbpa:GPHN.FingR-mScarlet-IL2RGTC-*

KRAB(A)-pA-CC2-Tol2 and a modified version of the PSD95 intrabody we previously published[24] for co-

expression experiments (*pEXPR-zfmbpa:PSD95.FingR-EGFP-CCR5TC-KRAB(A)-pA-CC2-Tol2)* from

VectorBuilder (see key resources table for Vector IDs). To create an entry plasmid encoding human GPHN

protein, we used plasmid *pECE-M2-GPHN* (Addgene plasmid #31665; RRID: Addgene_31665) and designed

primers that introduced a Kozak sequence and attB sites that flank the coding sequence. We amplified human

GPHN using Phusion polymerase, and then performed a gateway BP reaction with pDONR-221 to create a

middle entry *pME-GPHN*. This plasmid was used to create a plasmid to encode dominant negative GPHN as

described in Kim et al., 2021[36]. The PASVKDGYAVRAA amino acid sequence at residues 369-381 described in

Kim et al., 2021, corresponded to amino acids 405-417 in our *pME-GPHN* sequence. To create the dominant

negative mutation in the conserved protein sequence, we generated the amino acid change at G411D *in silico*

using SnapGene software (www.snapgene.com) and custom ordered the gene in the pDONR-221 vector from

ThermoFisher's GeneArt custom gene synthesis (figure 5). We also generated middle- and 3'-entry vectors

containing *mApple-CAAX* sequence. We used Gateway cloning to create a *pME-mApple-CAAX* vector and

InFusion cloning (Takara Bio, 638944) for a *p3E-mApple-CAAX-pA* vector (see key resources table for cloning

primers and entry plasmids). The Gateway system was subsequently used to clone these middle-entry vectors

and others into expression plasmids with the 5' entry *p5E-mbpa* plasmid to provide cis-regulatory elements and

3' reporter fluorophores following a T2A sequence (see expression vectors in key resources table).

Immunohistochemistry. Larvae were fixed in 4% PFA at each timepoint and washed with 1x PBS after 24 hr.

Larvae were then embedded in 1.2% agarose in sucrose, cut to blocks, and soaked in 30% sucrose overnight.

Blocks were then dried and frozen on dry ice and stored at -80° until sectioning. Blocks were sectioned on a

Leica 1950 cryostat in 20 μm thick sections and thaw-mounted to polarized slides. Slides were mounted in a

Sequenza rack followed by immunostaining as previously described[24,74] (Thermo Scientific, Waltham, MA).

Briefly, slides were washed with 1x PBSTx (0.1% Triton-X 100) 3 times for 5 min. Then, a block was added (2%

goat serum and 2% bovine serum albumin in 1xPBSTx) for 1 hr. Primary antibodies (see key resources table for

antibodies and concentrations) were diluted in block and added to slides and then stored overnight at 4°. The

next day, slides were washed in 1x PBSTx every 10 min for 1.5 hr, then secondary antibodies were diluted in block and added and incubated at room temperature for 2 hr (see key resources table for antibodies and concentrations). Secondaries were washed off in 1x PBSTx every 10 min for 1.5 hr, followed by DAPI for 5 min (optional, 1:2000 diluted in 1x PBSTx). For DAPI labeling, slides were washed 3 times for 5 min with 1x PBSTx, followed by mounting. Two drops of Vectashield (Vector Laboratories, H-1000-10) were added followed by application of a No.1 coverslip. Slides were sealed with clear nail polish and allowed to dry at room temperature for 15 min and stored at 4° until imaging. Axon class myelination experiments and total myelin in wildtype and mutant experiments were performed with fixed, transverse sections that were washed with PBSTx and mounted without immunostaining.

Imaging

Live Animal Fluorescent Imaging. Anesthetized larvae sorted for transgenesis reporters or identified as positive for spinal cord fluorescent reporter expression were imaged at 3 dpf, 4 dpf, and 7 dpf. Larvae were mounted in 0.9% agarose with 0.6% tricaine on their sides pressed against a coverslip and imaged on a spinning disk confocal microscope (Carl Zeiss, Oberkochen, Germany) or laser scanning confocal microscope (Carl Zeiss), with a 40x water objective. Individual dorsal OLs were imaged above the yolk sac extension. Standard confocal imaging was used to capture Z-stacks with 0.5 μm step intervals for sheath analysis. Super resolution Airyscan confocal imaging was used on the Zeiss 880 to acquire Z-stacks of individual OLs in *gphnb* and wild-type larvae carrying transgenic neuron reporters to analyze mutant and wild-type sheath length on axon classes with 0.225 μm step intervals. Airyscan imaging was also used to capture all intrabody images with 0.5 μm step intervals. If larvae required genotyping, individual larvae were extracted from the agarose following imaging and lysed with NaOH and Tris and genotyped as described above. Otherwise, larvae were euthanized after imaging.

Fixed Tissue Imaging. Transverse imaging was carried out on fixed, 20 μm thick cryosectioned tissue with a Zeiss LSM 880 Airyscan confocal microscope with a 40x oil objective and at least 1.8x zoom. To analyze Gphn localized to myelin on specific axon classes, we used an Andor Dragonfly 200 Spinning Disk Confocal (Oxford Instruments) DMi8 inverted microscope (Leica) with a 63x oil objective. For immunostaining, all images were

captured within 2 weeks of staining. For each larva, 3-5 images of the spinal cord were captured serially above

the yolk extension and data either summed or averaged by animal. All imaging parameters including Z-step

interval, frame size, bit depth, laser power, and gain were kept consistent within experiments.

Data Analysis

Image Blinding. All images were blinded prior to analysis. We used the FIJI (Fiji Is Just ImageJ)[78], image blinding

plugin Lab-utility-plugins/blind-files developed by Nick George and Wendy Macklin (https://github.com/Macklin-

Lab/imagej-microscopy-scripts), and only unblinded once analysis was complete.

Sheath Analysis. Sheath length was measured using FIJI with the Neuroanatomy plugin SNT (simple neurite

tracer)[79] as described previously[18,24,74,80]. A background subtraction with a rolling ball radius of 50 μm was

performed prior to analysis. Briefly, for individual OLs the length of each sheath was traced and length in μm was

measured. Each length measurement entry was then counted as an individual sheath and sheaths per cell were

summed. Sheath length was plotted for individual sheaths across all OLs analyzed, whereas sheath number and

cumulative sheath length were plotted by cell. For sheath length on axon class analysis in wild-type and *gphnb*

mutant larvae, images were first Airyscan processed using Zen Black (Carl, Zeiss, version 2.3 SP1). Imaris x64

(Oxford Instruments, 9.9.1-10.2.0) was used to trace sheaths and classify sheaths on reported axons. Sheaths

were traced using the Filaments tool, using the manual tracing feature. Individual sheaths were manually traced,

and detailed statistics captured for each filament length. Each sheath was then assessed whether it was

wrapping reporter axons. Individual sheath length on reporter axons were then plotted by genotype and neuron

reporter conditions.

Immunohistochemistry analysis. We used Imaris to quantify all immunostaining. With Gphn antibody staining

in wild-type and mutant larvae, images were first Airyscan processed for deconvolution in Zen Black. We then

performed background subtraction with a 15 μm radius, then cropped the stack to 20 μm. We then created a

surface object to quantify puncta with a background subtraction of 0.5 μm, and threshold 5% the maximum value,

followed by an intensity-based object splitting and a final volume of ≥ 0.00125 μm filter. A spinal cord surface was

created using the manual creation feature by drawing around the spinal cord on the last slice, duplicating this

surface onto the first slice, and creating the surface object from the drawn ROI. The Gphn surface object was

then filtered to signal within the spinal cord. We then gathered the specific, detailed volume statistics for total

puncta and volume per puncta for each genotype. Three images per larvae were analyzed, with the Gphn puncta

measure corrected for spinal cord volume for each image. The mean per fish was then calculated and plotted as

puncta per 100 μm^3.

For Gphn puncta in myelin experiments, images were Airyscan deconvoluted in Zen Black, followed by

Imaris background subtraction with a 15 μm radius for the myelin and Gphn channel. Images were then cropped

to the inner 20 μm slices from the Z-stack. A surface is created of the myelin channel similar to described above

for single OLs, with a background subtraction with diameter of largest sphere of 1 μm, followed by a manually

tuned threshold and a split objects filter of 2 μm to best match the fluorescent signal. Extraneous background

surfaces were manually deleted. Then, surfaces were created of the Gphn channel as described above in wild-

type and mutant conditions. This Gphn surface object was then filtered by distance to the myelin surface with a

distance of ≤ 0 μm and duplicated to a new surface. This distance to myelin filter captured the Gphn puncta

within the myelin surface. The specific, detailed volume statistics were then generated to provide total puncta

and volume per puncta for Gphn in myelin.

To quantify the Gphn puncta in myelin on axon classes, deconvolution was performed in Imaris using 10

iterations, followed by a background subtraction with a 15 μm radius for Gphn channel. We then created myelin

and Gphn surface objects as described above for the Gphn in myelin analysis. Once puncta in myelin were

duplicated to a new surface object, the slice view option was used with the neuron and myelin fluorescent

channels toggled on, and each punctum was manually assessed for whether it is in myelin on the reporter axon.

Puncta determined to be in myelin on the reporter axon were selected and duplicated to a new surface object

and the specific, detailed volume statistics were generated. The proportion of puncta in myelin on axon class

was then calculated by totaling the puncta in myelin on the reporter axons and dividing by the total puncta in

myelin (figure 3D).

Intrabody Analysis. Intrabody images were Airyscan deconvolution processed and analyzed in Imaris.

Background subtraction with a 15 μm radius was performed, then images were cropped to isolate single, dorsal

OLs. A surface was created of the OL with a background subtraction with diameter of largest sphere of 1 μm,

followed by a threshold that was manually tuned to best match the fluorescent signal. The split objects filter of 2

μm was also used to capture the OL surface more precisely. Intrabody surfaces were created using a background

subtraction with a diameter of largest sphere of 0.35 μm, and the threshold was manually adjusted to best match

fluorescent signal. The split objects filter of 0.5 μm was used, followed by a voxel filter to further eliminate creation

of any background surfaces. The intrabody signal was then filtered to within the OL surface, and any puncta

where majority of the volume resided outside of the OL surface with minimal volume inside the surface, and

puncta just touching the outside of the OL surface were manually deleted. Puncta in individual sheaths were

then manually duplicated to new surface objects and the detailed, specific statistics were used for puncta per

sheath quantification. Total puncta per OL was calculated with the summation of the puncta in individual sheaths.

This eliminated the bright, self-regulating expression in the cell body.

Myelinated axon counts analysis. Transverse images were processed and analyzed in Fiji. First, a background

subtraction with a 15 μm rolling ball radius was performed. Then, we created a new sub-stack of the inner 20 μm

slices and used the multi-point tool to identify every myelinated axon on one side of the spinal cord. These counts

were totaled and separated by region (dorsal white matter tract, medial white matter, and ventral white matter

tract). We analyzed 3 images per larvae that were then averaged. Single 0.5 mm sections were used for

representative images and the same region was isolated for magnified views between wild-type and *gphnb*

mutant larvae.

Behavior analysis. The DanioVision software (Noldus) recorded 10-min videos and used the EthoVision TX to

automatically track the movement of individual larvae. Total distance moved and velocity were generated and

used for analysis between wild-type and *gphnb* mutant larvae.

Statistical Analysis. All data analysis, statistics, and plotting were performed using R in R Studio (v

2024.04.2+764), except for behavior analysis which was performed in GaphPad Prism (version 10). Data and

statistical analysis were performed using the ggpubr and emmeans packages. Plots were generated with the

dplyr and ggplot2 packages. Data from each experiment were tested for normality with the Shapiro-Wilkes test.

If data were normally distributed (p>0.05), parametric tests were used to compare groups. If data were not

normally distributed, non-parametric tests were used. For tests with two groups, the student's T-Test or Wilcoxon

rank sum test were used. For datasets with multiple comparisons, global significance was tested with a one-way

Anova, Kruskal-Wallis test, or a type III two-way ANOVA for unbalanced design, followed by Bonferroni corrected

pair-wise T-Tests or Wilcoxon rank sum tests. All experiments were performed by 7 dpf when sex is not yet

determined in the zebrafish.

Key resources table.

Reagent or Resource	Source	Concentration	Identifier
Transgenic zebrafish lines			
Tg(mbpa:eGFP-CAAX)[co58]	Yergert et al., 2019; Doll et al., 2019	NA	ZDB-TGCONSTRUCT-200609-1
Tg2(mbpa:mCherry-CAAX)[co13]	Hughes and Appel, 2020	NA	ZDB-TGCONSTRUCT-210604-5
Tg(sox10:mRFP)[vu234]	Kucenas et al., 2008	NA	ZDB-TGCONSTRUCT-080321-2
TgBAC(slc17a6b:eGFP)	Hughes and Appel, 2020; Barker et al., 2022	NA	ZDB-TGCONSTRUCT-110413-4
Tg(slc6a5:eGFP)	McLean et al., 2007	NA	ZDB-TGCONSTRUCT-070514-1
TgBAC(gad1b:eGFP)	Male et al., 2020	NA	ZDB-TGCONSTRUCT-131127-6
Primer and gRNA sequences (5' to 3')			
TCTGCTCAGGCTTGTCAGTG	IDT	2.5 μM	*gphna* forward primer
ACAGACCAAAGGCAGCTCTC	IDT	2.5 μM	*gphna* reverse primer

GAGCGCTGAATCTGG GTTCT	IDT	2.5 μM	*gphnb* forward primer
CAAACAGCTGGAAAA CCGCA	IDT	2.5 μM	*gphnb* forward primer
CAACTCGGATTTGGT GGTCG	IDT	100 ng	*gphna* gRNA
TCAGGACGCCGACCC GGATT	IDT	100 ng	*gphnb* gRNA
GGGGACAAGTTTGTA CAAAAAAGCAGGCTT ATACGCCGCCACCAT GCCCGGGAATTCGGC	IDT	2.5 μM	pME-GPHN forward primer
GGGGACCACTTTGTA CAAGAAAGCTGGGTT TAGCCGTCCAATGAC CATGACA	IDT	2.5 μM	pME-GPHN reverse primer
GGGGACAAGTTTGTA CAAAAAAGCAGGCTT AATGGTGAGCAAGGG C	IDT	2.5 μM	pME-mApple-CAAX forward primer
GGGGACCACTTTGTA CAAGAAAGCTGGGTT TCAGGAGAGCAC	IDT	2.5 μM	pME-mApple-CAAX reverse primer
GATCCCATCGATTCG ATGGTGAGCAAGGGC GAG	IDT	2.5 μM	p3E-T2A-mApple-CAAX forward primer
GGCTGCAGAATCTAG TCAGGAGAGCACACA CTTG	IDT	2.5 μM	p3E-T2A-mApple-CAAX reverse primer
Enzymes			
BsiEI	New England Biolabs	0.5 μL in 25 μL	R0554S; gphnb[co94] genotyping
Plasmids			
pDONR-221	Kwan et al., 2007	NA	
pDEST-CC2-Tol2	Kwan et al., 2007	NA	
p5E-mbpa	Yergert et al., 2019	NA	
pME-mApple-CAAX	This paper	NA	
p3E-pA	Kwan et al., 2007	NA	
p3E-T2A-mcs-pA	Kwan et al., 2007	NA	
p3E-T2A-mApple-CAAX	This paper	NA	

*huβB1cry:*mApple-CAAX	Addgene	NA	RRID: Addgene_54567
pCAG_GPHN.FingR-mKate2-IL2RGTC	Addgene	NA	RRID: Addgene_46297
pECE-M2-GPHN	Addgene	NA	RRID: Addgene_31665
pME-dnGPHN	ThermoFisher	NA	
*pEXPR-zfmbpa:*Gphn.FingR-mScarlet-IL2RGTC-KRAB(A)-pA-CC2-Tol2	VectorBuilder	NA	Vector ID: VB240216-1031cjn
pEXPR-zfmbpa:PSD95.FingR-GFP-CC5TC-KRAB(A)-pA-CC2-Tol2	VectorBuilder	NA	Vector ID: VB240225-1266hew
pEXPR-mbpa:eGFP-CAAX-CR2-Tol2	Hughes and Appel, 2019; Yergert et al., 2019; Doll et al., 2019	NA	
pEXPR-mbpa:mApple-CAAX-CC2-Tol2	This paper	NA	
pEXPR-mbpa:GPHN-T2A-mApple-CAAX-CC2-Tol2	This paper	NA	
pEXPR-mbpa:dnGPHN-T2A-mApple-CAAX-CC2-Tol2	This paper	NA	

pEXPR-sox10(7.2):mScarlet-CAAX-CG2-Tol2	Yergert et al., 2019; Fedder-Semmes and Apple, 2021	NA	

Antibodies

mAb7a mouse monoclonal Gphn	Synaptic Systems	1:500	147 011
Living Colors® DsRed rabbit polyclonal	Takara Bio	1:500	632496
Alexa Fluor goat α-mouse 568	Invitrogen	1:500	A-11004
Alexa Fluor goat α-rabbit 568	Invitrogen	1:500	A-11011
Alexa Fluor goat α-mouse 647	Invitrogen	1:500	A-21235

Drugs

Tricaine methanesulfonate (Syncaine)	Syndel	4%	ANADA #200-226
Paraformaldehyde (PFA), 32%	Electron Microscopy Sciences	4%	15714-S
Tetrodotoxin (TTX)	Millipore Sigma	0.6mM	554412-1MG

Software

Zen Black (version 2.3 SP1)	Carl Zeiss		
Fusion software (version 2.4.0.14)	Oxford Instruments		

R Studio (version 2024.04.2+764)	Posit		
Imaris x64 (versions 9.9.1-10.1.1)	Oxford Instruments		
DanioVision	Noldus		
Prism (version 10)	GraphPad		

REFERENCES

1. Baumann, N. & Pham-Dinh, D. Biology of oligodendrocyte and myelin in the mammalian central nervous system. *Physiological Reviews* 81, 871–927 (2001).

2. Zhang, L., Poo, Mm. Electrical activity and development of neural circuits. *Nat Neurosci* **4** (Suppl 11), 1207–1214 (2001).

3. Tau, G., Peterson, B. Normal Development of Brain Circuits. *Neuropsychopharmacol* **35**, 147–168 (2010).

4. Kishore, S. et al. Systematic Shifts in the Balance of Excitation and Inhibition Coordinate the Activity of Axial Motor Pools at Different Speeds of Locomotion. *Journal of Neuroscience* **34:42**,14046-14054 (2014).

5. Cho, K. O., Hunt, C. A. & Kennedy, M. B. The rat brain postsynaptic density fraction contains a homolog of the Drosophila discs-large tumor suppressor protein. *Neuron.* **9**, 929–942 (1992).

6. Chen, X. et al. Mass of the Postsynaptic Density and Enumeration of Three Key *Molecules. Proc. Natl. Acad. Sci. USA* **102**, 11551–11556 (2005).

7. Kirsch, J., Wolters, I., Triller, A. *et al.* Gephyrin antisense oligonucleotides prevent glycine receptor clustering in spinal neurons. *Nature* **366**, 745–748 (1993).

8. Sassoè-Pognetto, M., Kirsch, J., Grünert, U., Greferath, U., Fritschy, J.M., Möhler, H., Betz, H. and Wässle, H. Colocalization of gephyrin and $GABA_A$-receptor subunits in the rat retina. J. Comp. Neurol., **357**: 1-14. (1995).

9. Essrich, C., Lorez, M., Benson, J. *et al.* Postsynaptic clustering of major $GABA_A$ receptor subtypes requires the γ2 subunit and gephyrin. *Nat Neurosci* **1**, 563–571 (1998).

10. Tomassy, G. S. *et al.* Distinct Profiles of Myelin Distribution Along Single Axons of Pyramidal Neurons in Neocortex. *Science* **344**, 319–324 (2014).

11. Call, C.L., Bergles, D.E. Cortical neurons exhibit diverse myelination patterns that scale between mouse brain regions and regenerate after demyelination. *Nat Commun* **12**, 4767 (2021).

12. Micheva, K. D. *et al.* A large fraction of neocortical myelin ensheathes axons of local inhibitory neurons. *eLife* **5**, 1–29 (2016).

13. Stedehouder, J. *et al.* Fast-spiking Parvalbumin Interneurons are Frequently Myelinated in the Cerebral
Cortex of Mice and Humans. *Cerebral Cortex* **27**, 5001–5013 (2017).

14. Zonouzi, M. *et al.* Individual Oligodendrocytes Show Bias for Inhibitory Axons in the Neocortex. *Cell
Reports* **27**, 2799–2808 (2019).

15. Almeida, R. G. *et al.* Myelination induces axonal hotspots of synaptic vesicle fusion that promote sheath
growth. *Current biology* **31**, 1–12 (2021).

16. Nelson, H. *et al.* Individual neuronal subtypes control initial myelin sheath growth and stabilization. *Neural
Development* **15**, 1–16 (2020).

17. Kukley, M., Capetillo-Zarate, E. & Dietrich, D. Vesicular glutamate release from axons in white matter.
Nature Neuroscience **10**, 311–320 (2007).

18. Hines, J. H., Ravanelli, A. M., Schwindt, R., Scott, E. K. & Appel, B. Neuronal activity biases axon
selection for myelination in vivo. *Nature Neuroscience* **18**, 683–689 (2015).

19. Mensch, S. *et al.* Synaptic vesicle release regulates myelin sheath number of individual oligodendrocytes
in vivo. *Nature Neuroscience* **18**, 628–630 (2015).

20. Zhang, Y. *et al.* An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and
Vascular Cells of the Cerebral Cortex. *Journal of Neuroscience* **34**, 11929–11947 (2014).

21. Marques, S. *et al.* Oligodendrocyte heterogeneity in the mouse juvenile and adult central nervous system.
Science **352**, 1326–1329 (2016).

22. Raj, B. *et al.* Simultaneous single-cell profiling of lineages and cell types in the vertebrate brain. *Nature
Biotechnology* **36**, 442–450 (2018).

23. Marisca, R. *et al.* Functionally distinct subgroups of oligodendrocyte precursor cells integrate neural
activity and execute myelin formation. *Nat Neurosci* (2020).

24. Hughes, A. N. & Appel, B. Oligodendrocytes express synaptic proteins that modulate myelin sheath
formation. *Nature Communications* **10**, 1–15 (2019).

25. Li, J., Miramontes, T. G., Czopka, T. & Monk, K. R. Synaptic input and Ca2+ activity in zebrafish
oligodendrocyte precursor cells contribute to myelin sheath formation. *Nat Neurosci* (2024).

26. Benamer, N., Vidal, M., Balia, M. & Angulo, M. C. Myelination of parvalbumin interneurons shapes the function of cortical sensory inhibitory circuits. *Nature Communications* **11**, 1–14 (2020).

27. Hamada MS, Popovic MA and Kole MHP. Loss of Saltation and Presynaptic Action Potential Failure in Demyelinated Axons. *Front. Cell. Neurosci*. 11:45 (2017).

28. Kim, J. H., Renden, R., and von Gersdorff, H. Dysmyelination of Auditory Afferent Axons Increases the Jitter of Action Potential Timing during High-Frequency Firing. *J Neurosci* **33(22)**:9402–9407 (2013).

29. Pajevic, S., Basser, P. J. & Fields, R. D. Role of myelin plasticity in oscillations and synchrony of neuronal activity. *Neuroscience* **276**, 135–147 (2014).

30. Gross, G. G. *et al.* Recombinant probes for visualizing endogenous synaptic proteins in living neurons. *Neuron* **78**, 971–985 (2013).

31. Meyer, A and Manfred Schartl, M. Gene and genome duplications in vertebrates: the one-to-four (-to-eight in fish) rule and the evolution of novel gene functions. *Current Opinion in Cell Biology* 11:6, 699-704 (1999).

32. Taylor, J. S., et al. Genome Duplication, a Trait Shared by 22,000 Species of Ray-Finned Fish. *Genome Research* **13** 382-390 (2003).

33. Feng, G. *et al.* Dual Requirement for Gephyrin in Glycine Receptor Clustering and Molybdoenzyme Activity. *Science* (1998).

34. Ogino, K. *et al.* Duplicated gephyrin genes showing distinct tissue distribution and alternative splicing patterns mediate molybdenum cofactor biosynthesis, glycine receptor clustering, and escape behavior in zebrafish. *Journal of Biological Chemistry* **286**, 806–817 (2011).

35. Brennan, E *et al.* A zebrafish *gephyrinb* mutant distinguishes synaptic and enzymatic functions of Gephyrin. N*eural Development* 19:14 (2024).

36. Kim, S. *et al.* Impaired formation of high-order gephyrin oligomers underlies gephyrin dysfunction-associated pathologies. *iScience* **24**, 102037 (2021).

37. Barres, B., Raff, M. Proliferation of oligodendrocyte precursor cells depends on electrical activity in axons. *Nature* **361**, 258–260 (1993).

38. Demerens, C. *et al.* Induction of myelination in the central nervous system by electrical activity. *Proceedings of the National Academy of Sciences of the United States of America* **93**, 9887–9892 (1996).

39. Liu J., Dietz K., DeLoyht J. M. *et al*. Impaired adult myelination in the prefrontal cortex of socially isolated mice. *Nature Neuroscience* **15**, 1621–1623 (2012).

40. Makinodan, M., Rosen, K. M., Ito, S. & Corfas, G. A critical period for social experience-dependent oligodendrocyte maturation and myelination. *Science* **337**, 1357–1360 (2012).

41. Gibson, E. M. *et al.* Neuronal Activity Promotes Oligodendrogenesis and Adaptive Myelination in the Mammalian Brain. *Science* **344**, 1252304-1-1252304–12 (2014).

42. Gautier H. O., Evans K. A., Volbracht K. *et al*. Neuronal activity regulates remyelination via glutamate signalling to oligodendrocyte progenitors. *Nat. Communications.* **6**, 8518 (2015).

43. Wake, H. *et al.* Nonsynaptic junctions on myelinating glia promote preferential myelination of electrically active axons. *Nature Communications* **6**, (2015).

44. Etxeberria A., Hokanson K. C., Dao D. Q., Mayoral S. R., Mei F., Redmond S. A., Ullian E. M. and Chan J. R. Dynamic modulation of myelination in response to visual stimuli alters optic nerve conduction velocity. *Journal of Neuroscience* **36**, 6937–6948 (2016).

45. Hughes, E. G., Orthmann-Murphy, J. L., Langseth, A. J. & Bergles, D. E. Myelin remodeling through experience-dependent oligodendrogenesis in the adult somatosensory cortex. *Nature Neuroscience* **21**, 696–706 (2018).

46. Mitew, S. *et al.* Pharmacogenetic stimulation of neuronal activity increases myelination in an axon-specific manner. *Nature Communications* **9**, 1–16 (2018).

47. Stedehouder, J., Brizee, D., Shpak, G. & Kushner, S. A. Activity-dependent myelination of parvalbumin interneurons mediated by axonal morphological plasticity. *Journal of Neuroscience* **38**, 3631–3642 (2018).

48. Bullock, P. N., and Rome, L. H. Glass micro-fibers: A model system for study of early events in myelination. *Journal of Neuroscience Research* **27**:3, 383-393 (1990).

49. Lee, S., Leach, M., Redmond, S. *et al.* A culture system to study oligodendrocyte myelination processes using engineered nanofibers. *Nat Methods* **9**, 917–922 (2012).

50. Bechler, M. E., Byrne, L., ffrench-Constant, Charles. CNS Myelin Sheath Lengths Are an Intrinsic Property of Oligodendrocytes. *Current Biology* **25**:18, 2411 - 2416 (2015).

51. Bergles, D. E., Roberts, J. D. B., Somogyi, P. & Jahr, C. E. Glutamatergic synapses on oligodendrocyte precursor cells in the hippocampus. *Nature* **405**, 187–191 (2000).

52. Lin, S. C. & Bergles, D. E. Synaptic signaling between GABAergic interneurons and oligodendrocyte precursor cells in the hippocampus. *Nature Neuroscience* **7**, 24–32 (2004).

53. Káradóttir, R., Cavelier, P., Bergersen, L. H. & Attwell, D. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. *Nature* **438**, 1162–1166 (2005).

54. Vélez-Fort, M. *et al.* Postnatal Switch from Synaptic to Extrasynaptic Transmission between Interneurons and NG2 Cells. *Journal of Neuroscience* **30** (20) 6921-6929 (2010).

55. Orduz, D. *et al.* Interneurons and oligodendrocyte progenitors form a structured synaptic network in the developing neocortex. *eLife* 1–53 (2015).

56. Mount, C. W., Yalçın, B., Cunliffe-Koehler, K., Sundaresh, S. & Monje, M. Monosynaptic tracing maps brain-wide afferent oligodendrocyte precursor cell connectivity. *eLife* **8**, 1–17 (2019).

57. Kuckley, M., Nishiyama, A., and Dietrich, D. The Fate of Synaptic Input to NG2 Glial Cells: Neurons Specifically Downregulate Transmitter Release onto Differentiating Oligodendroglial Cells. *Journal of Neuroscience* **30**:24, 8320-8331 (2010).

58. Baraban, M., Koudelka, S. & Lyons, D.A. Ca^{2+} activity signatures of myelin sheath formation and growth in vivo. *Nat Neurosci* **21**, 19–23 (2018).

59. Krasnow, A.M., Ford, M.C., Valdivia, L.E. *et al.* Regulation of developing myelin sheath elongation by oligodendrocyte calcium transients in vivo. *Nat Neurosci* **21**, 24–28 (2018).

60. Czopka, T., ffrench-Constant, C., and Lyons, D. A. Individual Oligodendrocytes Have Only a Few Hours in which to Generate New Myelin Sheaths In Vivo. *Developmental Cell* **25**:6, 599-609 (2013).

61. Arancibia-Cárcamo, I. L. *et al.* Node of ranvier length as a potential regulator of myelinated axon conduction speed. *eLife* **6**, 1–15 (2017).

62. Schmidt H, Knösche TR. Action potential propagation and synchronisation in myelinated axons. *PLoS Comput Biol* 15(10):e1007004 (2019).

63. Fotiadis, P., Cieslak, M., He, X. *et al.* Myelination and excitation-inhibition balance synergistically shape structure-function coupling across the human cortex. *Nat Commun* **14**, 6115 (2023).

64. Stadelmann, C., Timmler, S., Barrantes-Freer, A., Simons, M. Myelin in the Central Nervous System: Structure, Function, and Pathology. *Physiological Reviews* **99:3**, 1381-1431 (2019).

65. Maheras, K.J., Peppi, M., Ghoddoussi, F. *et al.* Absence of Claudin 11 in CNS Myelin Perturbs Behavior and Neurotransmitter Levels in Mice. *Sci Rep* **8**, 3798 (2018).

66. Noori, R. *et al.* Activity-dependent myelination: A glial mechanism of oscillatory self-organization in large-scale brain networks. *Proceedings of the National Academy of Sciences* 13–15 (2020).

67. Song, J., Saglam, A., Zuchero, J. B., Bush, V. P. Translating Molecular Approaches to Oligodendrocyte-Mediated Neurological Circuit Modulation. *Brain Sci.* **14(7)**, 648 (2024).

68. Pepper RE, Pitman KA, Cullen CL, and Young KM. How Do Cells of the Oligodendrocyte Lineage Affect Neuronal Circuits to Influence Motor Function, Memory and Mood? *Front. Cell. Neurosci.* **12**:399. (2018).

69. Hughes, A. N. & Appel, B. Microglia phagocytose myelin sheaths to modify developmental myelination. *Nature Neuroscience* **23**, 1055–1066 (2020).

70. Barker, C. M., Miles, K. D. & Doll, C. A. Fmrp regulates neuronal balance in embryonic motor circuit formation. *Frontiers in Neuroscience* **16**, 1–13 (2022).

71. McLean, D. L., Fan, J., Higashijima, S. I., Hale, M. E. & Fetcho, J. R. A topographic map of recruitment in spinal cord. *Nature* **446**, 71–75 (2007).

72. Male, I. *et al.* Hedgehog signaling regulates neurogenesis in the larval and adult zebrafish hypothalamus. (2019).

73. Kucenas, S., Takada, N., Park, HC. *et al.* CNS-derived glia ensheath peripheral nerves and mediate motor root development. *Nature Neuroscience* **11**, 143–151 (2008).

74. Doll, C. A., Yergert, K. M. & Appel, B. H. The RNA binding protein fragile X mental retardation protein promotes myelin sheath growth. *Glia* 1–14 (2019).

75. Yergert, K. M., Doll, C. A., O'Rouke, R., Hines, J. H. & Appel, B. Identification of 3′ UTR motifs required for mRNA localization to myelin sheaths in vivo. *PLOS Biology* **19**, (2021).

76. Concordet, J-P and Haeussler, M. CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing
experiments and screens. *Nucleic Acids Research* **46:W1**, W242–W245, (2018).

77. Kwan, K. M. *et al.* The Tol2kit: A multisite gateway-based construction Kit for Tol2 transposon
transgenesis constructs. *Developmental Dynamics* **236**, 3088–3099 (2007).

78. Schindelin, J., Arganda-Carreras, I., Frise, E. *et al.* Fiji: an open-source platform for biological-image
analysis. *Nat Methods* **9**, 676–682 (2012).

79. Arshadi, C., Günther, U., Eddison, M. *et al.* SNT: a unifying toolbox for quantification of neuronal
anatomy. *Nat Methods* **18**, 374–377 (2021).

80. Fedder-Semmes, K. N. & Appel, B. The Akt-mTOR pathway drives myelin sheath growth by regulating
cap-dependent translation. *The Journal of Neuroscience* **41**, JN-RM-0783-21 (2021).

Acknowledgments:

We thank the Appel lab for comments on the manuscript. We also thank Dr. Angie Ribera for the *Tg(slc6a5:eGFP)* line, Dr. Rolf Karlstrom for the *TgBAC(gad1b:eGFP)* line, Dr. Don Arnold for *pCAG_GPHN.FingR-mKate2-IL2RGTC*, Dr. Thomas Schilling for *huβB1cry:mApple-CAAX*, and Dr. Anne Brunet for *pECE-M2-GPHN*. Finally, we thank the superb staff in our Zebrafish Core Facility for animal care.

Funding:

This work was supported by National Institutes of Health (NIH) grants 1F31NS125915 to N.J.C. and 1R35NS122191 to B.A. and a gift from the Gates Frontiers Fund to B.A.

Author contributions:

N.J.C. and B.A. conceived the project. C.A.D performed behavior experiments and analysis. B.A. made the *pME-mApple-CAAX* and *p3E-T2A-mApple-CAAX* plasmids. N.J.C. designed and performed all other experiments and analyzed all other data. N.J.C. wrote, and N.J.C., C.A.D., and B.A. edited the manuscript.

Data, code, and materials availability:

All data are available in the manuscript, Extended Data, or Source Data files. Raw images, R code, plasmid constructs, and zebrafish lines are available upon request.

Declaration of interests:

None.